tirzepatide surpass-4 reduces albuminuria among adults with type 2 diabetes in SURPASS trials SURPASS-CVOT trial: Tirzepatide was non-inferior

JCEM Case Reports

The glucagon receptor component appears to create a compounding effect that becomes more significant the longer treatment continues

These results demonstrated that higher tirzepatide doses produce dose-dependent weight loss and metabolic improvements, though they also correlated with increased nausea in early treatment phases

FG reports consultancies or paid advisory board memberships for Eli Lilly, Medtronic, Novo Nordisk, Roche Diabetes Care, and Sanofi

These injectable medications represent different stages in the evolution of weight management pharmacology

The self-reported average of 29.3 lbs in six months is based on data from 111 self-selected members using injectable GLP-1s combined with diet and exercise, and may not represent typical results